or Try an Advanced Search...

    Technical Analysis for INVA - Innoviva, Inc.

    Grade Last Price % Change Price Change
    C 18.60 0.16% 0.03
    INVA closed up 0.22 percent on Thursday, January 23, 2025, on 53 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Flat Up
    Historical INVA trend table...
    Date Alert Name Type % Chg
    Crossed Above 50 DMA Bullish 0.16%
    MACD Bullish Centerline Cross Bullish 0.16%
    180 Bullish Setup Bullish Swing Setup 0.16%
    Upper Bollinger Band Walk Strength 0.16%
    Overbought Stochastic Strength 0.16%
    Fell Below 50 DMA Bearish 0.38%
    Upper Bollinger Band Walk Strength 0.38%
    Overbought Stochastic Strength 0.38%
    Upper Bollinger Band Touch Strength 0.38%
    Crossed Above 50 DMA Bullish -0.80%
    Older End-of-Day Signals for INVA ...

       Recent Intraday Alerts

    Alert Time
    50 DMA Support 27 minutes ago
    Bullish 180 Entry about 1 hour ago
    Rose Above Previous Day's High about 1 hour ago
    Fell Below 50 DMA about 1 hour ago
    Reversed from Down about 20 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    INVA Chart by TradingView

    Profile

    Innoviva, Inc. Description

    Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Drugs Asthma Chronic Obstructive Pulmonary Disease Pulmonary Disease Glucocorticoids Antero Organofluorides Respiratory Products Combination Drugs Corticosteroid Fluticasone

    Is INVA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Dec 25 Innoviva's (NASDAQ:INVA) investors will be pleased with their 26% return over the last five years
    Dec 17 Innoviva enters distribution, license agreement with Basilea for Zevtera
    Dec 16 Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera® (ceftobiprole)
    Nov 26 Innoviva to Participate in the Citi 2024 Global Healthcare Conference
    Nov 22 Two In Vitro Studies on Eravacycline (XERAVA®) Presented at IDWeek, Demonstrating Its Sustained and Robust Antimicrobial Activity
    Nov 12 Innoviva to Participate in the UBS Global Healthcare Conference
    Nov 8 Innoviva Third Quarter 2024 Earnings: EPS: US$0.019 (vs US$1.26 in 3Q 2023)
    Nov 7 Innoviva GAAP EPS of $0.02, revenue of $89.51M beats by $12.59M
    Nov 6 Innoviva: Q3 Earnings Snapshot
    Nov 6 Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress
    See more INVA news...

    Comments

    Indicators

    Indicator Value
    52 Week High 21.28
    52 Week Low 14.325
    Average Volume 740,458
    200-Day Moving Average 17.81
    50-Day Moving Average 18.52
    20-Day Moving Average 17.80
    10-Day Moving Average 18.08
    Average True Range 0.33
    RSI (14) 60.78
    ADX 28.76
    +DI 29.83
    -DI 24.66
    Chandelier Exit (Long, 3 ATRs) 17.89
    Chandelier Exit (Short, 3 ATRs) 18.01
    Upper Bollinger Bands 18.78
    Lower Bollinger Band 16.81
    Percent B (%b) 0.89
    BandWidth 11.12
    MACD Line 0.03
    MACD Signal Line -0.16
    MACD Histogram 0.1912
    Fundamentals Value
    Market Cap 1.16 Billion
    Num Shares 62.6 Million
    EPS 0.81
    Price-to-Earnings (P/E) Ratio 22.93
    Price-to-Sales 3.30
    Price-to-Book 1.74
    PEG Ratio 0.24
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 19.14
    Resistance 3 (R3) 19.08 18.82 19.05
    Resistance 2 (R2) 18.82 18.68 18.86 19.01
    Resistance 1 (R1) 18.70 18.59 18.76 18.76 18.98
    Pivot Point 18.44 18.44 18.48 18.48 18.44
    Support 1 (S1) 18.32 18.30 18.38 18.38 18.16
    Support 2 (S2) 18.06 18.21 18.10 18.13
    Support 3 (S3) 17.94 18.06 18.10
    Support 4 (S4) 18.00